- Home
- SLG vs RARE Comparison
SLG vs RARE Comparison
Compare SLG & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLG
- RARE
- Stock Information
- Founded
- SLG 1980
- RARE 2010
- Country
- SLG United States
- RARE United States
- Employees
- SLG N/A
- RARE N/A
- Industry
- SLG Real Estate Investment Trusts
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- SLG Real Estate
- RARE Health Care
- Exchange
- SLG Nasdaq
- RARE Nasdaq
- Market Cap
- SLG 5.3B
- RARE 5.2B
- IPO Year
- SLG 1997
- RARE 2014
- Fundamental
- Price
- SLG $68.02
- RARE $43.98
- Analyst Decision
- SLG Hold
- RARE Strong Buy
- Analyst Count
- SLG 15
- RARE 14
- Target Price
- SLG $68.67
- RARE $88.43
- AVG Volume (30 Days)
- SLG 1.4M
- RARE 717.6K
- Earning Date
- SLG 01-22-2025
- RARE 02-13-2025
- Dividend Yield
- SLG 4.41%
- RARE N/A
- EPS Growth
- SLG N/A
- RARE N/A
- EPS
- SLG N/A
- RARE N/A
- Revenue
- SLG $920,135,000.00
- RARE $522,745,000.00
- Revenue This Year
- SLG N/A
- RARE $27.36
- Revenue Next Year
- SLG $5.30
- RARE $18.61
- P/E Ratio
- SLG N/A
- RARE N/A
- Revenue Growth
- SLG N/A
- RARE 27.44
- 52 Week Low
- SLG $41.81
- RARE $37.02
- 52 Week High
- SLG $82.81
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- SLG 34.09
- RARE 33.50
- Support Level
- SLG $66.65
- RARE $41.45
- Resistance Level
- SLG $76.49
- RARE $50.00
- Average True Range (ATR)
- SLG 2.70
- RARE 1.83
- MACD
- SLG -0.90
- RARE -0.31
- Stochastic Oscillator
- SLG 10.90
- RARE 26.55
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.